Chemotherapeutic effects of MEK kinase inhibitor and BRAF kinase inhibitor on KRAS-mutated human colon cancer cell lines with different microsatellite instability-Reference-Cited by-同舟云学术

Chemotherapeutic effects of MEK kinase inhibitor and BRAF kinase inhibitor on KRAS-mutated human colon cancer cell lines with different microsatellite instability

Published:2020-10-14 Issue:8 Volume:32 Page:437-444
ISSN:1120-009X
Container-title:Journal of Chemotherapy
language:en
Short-container-title:Journal of Chemotherapy

Author:

Kim Kyung-Ok¹,Park Woo-Jae²³,Jung YunJae³⁴,Lee Won-Suk⁵

Affiliation:

1. Gachon Medical Research Institute, Gil Medical Center, Gachon University, Incheon, Korea

2. Department of Biochemistry, College of Medicine, Gachon University, Incheon, Korea

3. Gachon Advanced Institute for Health Science & Technology, Gachon University, Incheon, Korea

4. Department of Microbiology, College of Medicine, Gachon University, Incheon, Korea

5. Department of Surgery and Peritoneal Surface Malignancy Clinic, Gil Medical Center, College of Medicine, Gachon University, Incheon, Korea

Funder

the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education

the Ministry of Science and ICT to Y. Jung.

Publisher

Informa UK Limited

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/1120009X.2020.1829326

Reference31 articles.

1. International WCRF. Colorectal cancer statistics. London, England: International WCRF; 2019.

2. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment

3. Network NCC. NCCN guidelines. PA, USA: Network NCC; 2017.

4. K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

5. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. AD80, a multikinase inhibitor, as a potential drug candidate for colorectal cancer therapy;Life Sciences;2022-11

2. The association between ERK inhibitor sensitivity and molecular characteristics in colorectal cancer;Biochemical and Biophysical Research Communications;2021-06